Breast Cancer Clinical Trial
Official title:
Effectiveness of a Combined Diet and Mindfulness Program on Weight Loss in Breast Cancer Survivors: A Randomized Controlled Trial
The study addresses the pressing issue of overweight and obesity among breast cancer patients, which exacerbates recurrence rates and mortality risks. Its primary objective is to assess the efficacy of two intervention models, the Diet, Exercise, and Mindfulness (DEM) model and the Diet and Exercise (DE) model, in facilitating weight loss, enhancing self-efficacy, mindfulness, and quality of life. The anticipated outcomes include long-term engagement in online self-learning, overcoming the limitations of ineffective self-management learning, and empowering healthcare professionals with scenario-based teaching materials. Through online platforms, patients can learn and review without constraints, ultimately achieving a holistic balance among physical, mental, and spiritual health.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - stage I-III breast cancer and completed treatment - Body mass index (BMI) is greater than or equal to 24 kg/m2 - possess a smartphone Exclusion Criteria: - Pregnant or planning to become pregnant within six months - Those who are unable to walk |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Yang Ming Chiao Tung University | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Yang Ming Chiao Tung University |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physiological indicator I | BMI in kg/m2 (weight in kilograms divided by height in meters squared) | baseline, 8 weeks, 24 weeks, 48 weeks | |
Primary | Physiological indicator II | Waist circumference in centimeter | baseline, 8 weeks, 24 weeks, 48 weeks | |
Primary | Physiological indicator III | Body fat in percentage | baseline, 8 weeks, 24 weeks, 48 weeks | |
Primary | Physiological indicator IV | Muscle mass in kilograms | baseline, 8 weeks, 24 weeks, 48 weeks | |
Primary | Food Intake Frequency | Food Frequency Questionnaire | baseline, 8 weeks, 24 weeks, 48 weeks | |
Primary | Mindful Awareness Attention | The minimum value is 1 and maximum value is 6, and higher scores mean a better outcome. | baseline, 8 weeks, 24 weeks, 48 weeks | |
Secondary | Weight Efficacy Lifestyle Questionnaire | The minimum value is 0 and maximum value is 10, and higher scores mean a better outcome. | baseline, 8 weeks, 24 weeks, 48 weeks | |
Secondary | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire | Item 1 to 28 the minimum value is 1 and maximum value is 4, and lower scores mean a better outcome.
Item 29 to 30 the minimum value is 1 and maximum value is 7, and higher scores mean a better outcome. |
baseline, 8 weeks, 24 weeks, 48 weeks | |
Secondary | Breast Cancer-Specific Quality of Life Questionnaire | The minimum value is 1 and maximum value is 4, and lower scores mean a better outcome. | baseline, 8 weeks, 24 weeks, 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |